Volgen
Gertjan Wolbink
Gertjan Wolbink
Reade
Geverifieerd e-mailadres voor reade.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
EA Stahl, S Raychaudhuri, EF Remmers, G Xie, S Eyre, BP Thomson, Y Li, ...
Nature genetics 42 (6), 508-514, 2010
14572010
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?
WK Lagrand, CA Visser, WT Hermens, HWM Niessen, FWA Verheugt, ...
Circulation 100 (1), 96-102, 1999
13651999
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
GM Bartelds, CLM Krieckaert, MT Nurmohamed, PA van Schouwenburg, ...
Jama 305 (14), 1460-1468, 2011
8412011
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
DJ Lovell, N Ruperto, S Goodman, A Reiff, L Jung, K Jarosova, ...
New England Journal of Medicine 359 (8), 810-820, 2008
7112008
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
GM Bartelds, CA Wijbrandts, MT Nurmohamed, S Stapel, WF Lems, ...
Annals of the rheumatic diseases 66 (7), 921-926, 2007
6782007
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink, M Vis, W Lems, AE Voskuyl, E De Groot, MT Nurmohamed, ...
Arthritis & Rheumatism 54 (3), 711-715, 2006
6042006
Common variants at CD40 and other loci confer risk of rheumatoid arthritis
S Raychaudhuri, EF Remmers, AT Lee, R Hackett, C Guiducci, NP Burtt, ...
Nature genetics 40 (10), 1216-1223, 2008
5882008
Rituximab treatment in patients with primary Sjögren's syndrome: an open‐label phase II study
J Pijpe, GW Van Imhoff, FKL Spijkervet, JLN Roodenburg, GJ Wolbink, ...
Arthritis & Rheumatism 52 (9), 2740-2750, 2005
5882005
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction
WK Lagrand, HWM Niessen, GJ Wolbink, LH Jaspars, CA Visser, ...
Circulation 95 (1), 97-103, 1997
5701997
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
PA Van Schouwenburg, T Rispens, GJ Wolbink
Nature Reviews Rheumatology 9 (3), 164-172, 2013
4662013
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk
S Raychaudhuri, BP Thomson, EF Remmers, S Eyre, A Hinks, C Guiducci, ...
Nature genetics 41 (12), 1313-1318, 2009
3792009
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.
GJ Wolbink, MC Brouwer, S Buysmann, IJ Ten Berge, CE Hack
The Journal of Immunology 157 (1), 473-479, 1996
3261996
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study
WH Bos, GJ Wolbink, M Boers, GJ Tijhuis, N de Vries, ...
Annals of the rheumatic diseases 69 (3), 490-494, 2010
3182010
Inhibition of human complement by β‐glycyrrhetinic acid
BH Kroes, CJ Beukelman, AJJ Van Den Berg, GJ Wolbink, H Van Dijk, ...
Immunology 90 (1), 115-120, 1997
2991997
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
GM Bartelds, CA Wijbrandts, MT Nurmohamed, S Stapel, WF Lems, ...
Annals of the rheumatic diseases 69 (5), 817-821, 2010
2922010
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
L Carmona, MA Descalzo, E Perez-Pampin, D Ruiz-Montesinos, A Erra, ...
Annals of the rheumatic diseases 66 (7), 880-885, 2007
2702007
A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells
CE Hack, GJ Wolbink, C Schalkwijk, H Speijer, WT Hermens, ...
Immunology today 18 (3), 111-115, 1997
2671997
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
CL Krieckaert, MT Nurmohamed, GJ Wolbink
Annals of the rheumatic diseases 71 (11), 1914-1915, 2012
2662012
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink, AE Voskuyl, WF Lems, E De Groot, MT Nurmohamed, PP Tak, ...
Annals of the rheumatic diseases 64 (5), 704-707, 2005
2642005
Development of the anti–citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis
LA van de Stadt, MHMT de Koning, RJ van de Stadt, G Wolbink, ...
Arthritis & Rheumatism 63 (11), 3226-3233, 2011
2622011
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20